6 7 More than 10% of the global population suffers from chronic kidney disease (CKD) 8 and
its prevalence is rising due to an aging population and an increase in the 9 number of …

Background Arterial stiffness is an independent predictor of all-cause and cardiovascular
mortality in patients with chronic kidney disease (CKD). There are limited prospective data …

Background High fibroblast growth factor-23 (FGF-23) levels are associated with adverse
outcomes. We studied the responsiveness of FGF-23 and mineral metabolism to altered …

Introduction Patients with chronic kidney disease (CKD) are at heightened cardiovascular
risk, which has been associated with abnormalities of bone and mineral metabolism. A …

Background Left ventricular hypertrophy (LVH) is a common cardiovascular disorder and an
independent risk factor for cardiovascular death in dialysis patients. Hyperphosphatemia is …

Background Disordered mineral metabolism is implicated in the pathogenesis of vascular
calcification in hemodialysis (HD) patients. Fibroblast growth factor 23 (FGF-23) is the main …

Background Genz-644470 is a new, nonabsorbed phosphate binding polymer. In an in vitro
competitive phosphate binding assay, Genz-644470 bound significantly more phosphate …

Fibroblast growth factor (FGF)-23 is probably the most important regulator of serum
phosphate and calcitriol (1, 25 (OH) 2 D 3) levels. It is secreted by osteocytes and …

Background Vascular calcification (VC) contributes to high mortality rates in chronic kidney
disease (CKD). High serum phosphate and FGF23 levels and impaired phosphaturic …

The kidneys excrete excess dietary phosphate, and patients with chronic kidney disease
may suffer from phosphate overload and hyperphosphatemia. In chronic kidney disease …